Latham & Watkins Advises OrganOx in US$1.5 Billion Acquisition by Terumo Corporation

Terumo Corporation (TSE: 4543, Terumo) has announced that Terumo has entered into a definitive agreement dated August 23, 2025, with OrganOx Limited (OrganOx), a leading innovator in organ preservation devices, and its shareholders to acquire all outstanding shares of OrganOx. Upon completion of the transaction, OrganOx will become a wholly owned subsidiary of Terumo. The total transaction value is approximately US$1.5 billion.

Latham & Watkins is advising OrganOx in the transaction with a corporate deal team led by London partner Robbie McLaren, Co-Chair of the firm’s Healthcare & Life Sciences Industry Group, and US-based partners Ross McAloon and Charles Ruck, with associates Samantha Peacock, Antonina Semyachkova, and Joanne Amos, with assistance from Elliot Brownlee. Advice was also provided on healthcare and life sciences matters by Washington, D.C. partner Elizabeth Richards, Bay Area partner Betty Pang, and Washington D.C. counsel Chad Jennings, with associate Oliver Mobasser; on tax matters by London partner Sean Finn, with associate Abi Abbott; on employment matters by Bay Area partner Maj Vaseghi and London partner Kendall Burnett, with associate Venice Ma; and on antitrust, CFIUS, and FDI matters by Brussels partner Hector Armengod, Washington, D.C. partner Patrick English and counsel Catherine Hein, and Brussels counsel Philipp Studt, with associates Christine Kalpin and Nathaniel Amann, with assistance from Klearchos Lazanas.